Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.
-
Meredith L, Chao T, Nevler A, Basu Mallick A, Singla RK, McCue PA, Bowne WB, Jiang W. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report. Diagn Pathol. 2023 Apr 11; 18(1):45.
-
Hernandez-Lara MA, Yadav SK, Shah SD, Okumura M, Yokoyama Y, Penn RB, Kambayashi T, Deshpande DA. Regulation of Airway Smooth Muscle Cell Proliferation by Diacylglycerol Kinase: Relevance to Airway Remodeling in Asthma. Int J Mol Sci. 2022 Oct 06; 23(19).
-
Chlopek M, Lasota J, Thompson LDR, Szczepaniak M, Kuzniacka A, Hincza K, Kubicka K, Kaczorowski M, Newford M, Liu Y, Agaimy A, Biernat W, Durzynska M, Dziuba I, Hartmann A, Inaguma S, Izycka-Swieszewska E, Kato H, Kopczynski J, Michal M, Michal M, Peksa R, Prochorec-Sobieszek M, Starzynska A, Takahashi S, Wasag B, Kowalik A, Miettinen M. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. Mod Pathol. 2022 11; 35(11):1609-1617.
-
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N, Lehrke M. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 2022 11; 24(11):2263-2272.
-
Wang D, Eisen HJ. Mechanistic Target of Rapamycin (mTOR) Inhibitors. Handb Exp Pharmacol. 2022; 272:53-72.
-
Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021 11 08; 6(1):379.
-
Kar AN, Lee SJ, Sahoo PK, Thames E, Yoo S, Houle JD, Twiss JL. MicroRNAs 21 and 199a-3p Regulate Axon Growth Potential through Modulation of Pten and mTor mRNAs. eNeuro. 2021 Jul-Aug; 8(4).
-
Pathak P, Blech-Hermoni Y, Subedi K, Mpamugo J, Obeng-Nyarko C, Ohman R, Molloy I, Kates M, Hale J, Stauffer S, Sharan SK, Mankodi A. Myopathy associated LDB3 mutation causes Z-disc disassembly and protein aggregation through PKCa and TSC2-mTOR downregulation. Commun Biol. 2021 03 19; 4(1):355.
-
Eisen HJ. CAVEAT mTOR: You've heard about the benefits of using mTOR inhibitors, here are some of the risks. Am J Transplant. 2021 02; 21(2):449-450.
-
Zhang A, Duchatelet S, Lakdawala N, Tower RL, Diamond C, Marathe K, Hill I, Richard G, Diab Y, Kirkorian AY, Watanabe F, Siegel DH, Hovnanian A. Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome. JAMA Dermatol. 2020 02 01; 156(2):196-200.